Author: Ravi Shankar

HOUSTON and LONDON, Sept. 28, 2026 (GLOBE NEWSWIRE) — Baker Hughes (NASDAQ: BKR) will announce the results of the third quarter ending Sept. 30, 2026, via press release at 5 p.m. Eastern Time (4 p.m. Central Time) on Tuesday, Oct. 27, 2026. A webcast to discuss the results will be held Wednesday, Oct. 28, 2026, at 9:30 a.m. Eastern Time (8:30 a.m. Central Time).

To access the webcast, listeners should visit the Baker Hughes website at: investors.bakerhughes.com. An archived version will be available on the website following the webcast.

About Baker Hughes
Baker Hughes (NASDAQ: BKR) is an energy technology company that provides solutions to energy and industrial customers worldwide. Built on a century of experience and conducting business in over 120 countries, our innovative technologies and services are taking energy forward – making it safer, cleaner and more efficient for people and the planet. Visit us at bakerhughes.com.

For more information, please contact:

Investor Relations
Chase Mulvehill
+1 346-297-2561
investor.relations@bakerhughes.com

Media Relations
Adrienne M. Lynch
+1 713-906-8407
media.relations@bakerhughes.com

– ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors –

NEW HAVEN, Conn., Sept. 28, 2026 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the first participant has been dosed in its Phase 1/2 clinical trial of ARV-6723, an investigational, oral PROteolysis TArgeting Chimera (PROTAC) designed to degrade hematopoietic progenitor kinase 1 (HPK1) in advanced solid tumors. ARV-6723 is Arvinas’ first clinical candidate in immuno-oncology (IO) and the first HPK1 PROTAC degrader to enter the clinic in the United States.

HPK1 acts as a negative regulator of immune activation and is expressed across multiple cell types including T cells, B cells, natural killer cells, and dendritic cells, making it a compelling IO target. HPK1 also plays an important role in shaping the tumor microenvironment. ARV-6723 is designed to degrade and remove the HPK1 protein and its signaling scaffolding, potentially addressing functions of HPK1 that may not be fully addressed by traditional inhibitors.

In preclinical studies, ARV-6723 demonstrated potent and selective HPK1 degradation, enhanced immune activity, and antitumor activity as a single agent and in combination with an immune checkpoint inhibitor across tumor models with differing levels of immune responsiveness, including multiple anti-PD-1-resistant models. Notably, in seven preclinical models, ARV-6723 demonstrated meaningful single-agent activity where neither an HPK1 inhibitor nor anti-PD-1 therapy showed benefit. These data support the clinical evaluation of ARV-6723 both as monotherapy and in combination with an anti-PD-1 therapy.

“The advancement of ARV-6723 into the clinic represents an important step in expanding the application of targeted protein degradation into immuno-oncology,” said Randy Teel, Ph.D., President and Chief Executive Officer at Arvinas. “Resistance to immunotherapy remains a significant challenge; to date, combinations targeting other immune pathways have not provided a reliable way to prevent or reverse it. The encouraging preclinical data for ARV-6723 – including activity in models resistant to immune checkpoint inhibitors – support clinical investigation of its potential to address this unmet need for patients.”

The ARV-6723-101 Phase 1/2 clinical trial (NCT07749586) is a global, multicenter trial designed to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of orally administered ARV-6723 as a monotherapy or in combination with pembrolizumab in adults with advanced solid tumors. The first-in-human trial will initially evaluate the safety of ARV-6723 as a monotherapy treatment and subsequently in combination with an anti-PD-1 therapy, while also evaluating whether deep and sustained HPK1 degradation translates into meaningful antitumor effects in patients. The initial monotherapy cohort of this trial is enrolling patients who have received a prior immune checkpoint inhibitor and have no suitable standard treatment options.

About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas, with its partner Pfizer, developed the first U.S. Food and Drug Administration (FDA)-approved PROTAC, a type of heterobifunctional protein degrader, which has been outlicensed to Rigel Pharmaceuticals, Inc. for exclusive global development, manufacturing, and commercialization.

Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle for spinal-bulbar muscular atrophy, also known as Kennedy’s disease; and ARV-6723, targeting HPK1 for advanced solid tumors. Arvinas has also advanced ARV-806, targeting KRAS G12D for solid tumors, in the clinic, and previously announced plans to seek an out-licensing agreement for any additional clinical trials of ARV-806, including dose expansion or combination clinical trials. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.

About ARV-6723
ARV-6723 is an investigational, oral PROTAC designed to degrade hematopoietic progenitor kinase 1 (HPK1) and is Arvinas’ first clinical candidate in the immuno-oncology space. HPK1 is a negative regulator of immune activation expressed across multiple immune cell types, including T cells, B cells, natural killer cells, and dendritic cells. Preclinically, ARV-6723 demonstrated potent, selective HPK1 degradation and greater tumor growth inhibition across low- and high-immunogenic tumor models, including anti-PD-1 resistant tumor models. By removing HPK1, ARV-6723 may address both its kinase-dependent and kinase-independent functions and enhance antitumor immune activity. ARV-6723 is currently being evaluated in a first-in-human Phase 1/2 clinical trial in patients with advanced solid tumors.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding: the potential of ARV-6723, including its degradation of hematopoietic progenitor kinase 1 (“HPK1”), and its potential treatment of advanced solid tumors; whether by removing HPK1, ARV-6723 may address both its kinase-dependent and kinase-independent functions and enhance antitumor immune activity; preclinical ARV-6723 data supporting the clinical evaluation of ARV-6723 both as monotherapy and in combination with an anti-PD-1 therapy; whether ARV-6723’s design to degrade and remove the HPK1 protein and its signaling scaffolding will address functions of HPK1 that may not be fully addressed by traditional inhibitors; Arvinas’ plans with respect to ARV-6723 and its development; and Arvinas’ plans to outlicense ARV-806. All statements, other than statements of historical fact, contained in this press release, including statements regarding Arvinas’ strategy, development plans, future operations, prospects, plans, and objectives of management and the statements identified in the prior paragraph, are forward-looking statements. The words “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “target,” “goal,” “aim,” “whether,” “will,” “would,” “could,” “reliance,” “should,” “look forward,” “seek,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Arvinas may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: whether Arvinas will be able to successfully conduct and complete development for its product candidates, including ARV-6723, on its current timelines or at all; risks related to clinical trial results and the interpretation thereof, including with respect to ARV-6723; that the results of preclinical studies may not be predictive of the results of clinical trials; Arvinas’ ability to protect its intellectual property portfolio; Arvinas’ reliance on third parties; whether Arvinas will be able to raise capital when needed; whether Arvinas’ cash and cash equivalents will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the “Risk Factors” section of Arvinas’ Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent other reports filed with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas’ current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas’ views as of any date subsequent to the date of this release.

Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com

Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com

– ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors –

NEW HAVEN, Conn., Sept. 28, 2026 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the first participant has been dosed in its Phase 1/2 clinical trial of ARV-6723, an investigational, oral PROteolysis TArgeting Chimera (PROTAC) designed to degrade hematopoietic progenitor kinase 1 (HPK1) in advanced solid tumors. ARV-6723 is Arvinas’ first clinical candidate in immuno-oncology (IO) and the first HPK1 PROTAC degrader to enter the clinic in the United States.

HPK1 acts as a negative regulator of immune activation and is expressed across multiple cell types including T cells, B cells, natural killer cells, and dendritic cells, making it a compelling IO target. HPK1 also plays an important role in shaping the tumor microenvironment. ARV-6723 is designed to degrade and remove the HPK1 protein and its signaling scaffolding, potentially addressing functions of HPK1 that may not be fully addressed by traditional inhibitors.

In preclinical studies, ARV-6723 demonstrated potent and selective HPK1 degradation, enhanced immune activity, and antitumor activity as a single agent and in combination with an immune checkpoint inhibitor across tumor models with differing levels of immune responsiveness, including multiple anti-PD-1-resistant models. Notably, in seven preclinical models, ARV-6723 demonstrated meaningful single-agent activity where neither an HPK1 inhibitor nor anti-PD-1 therapy showed benefit. These data support the clinical evaluation of ARV-6723 both as monotherapy and in combination with an anti-PD-1 therapy.

“The advancement of ARV-6723 into the clinic represents an important step in expanding the application of targeted protein degradation into immuno-oncology,” said Randy Teel, Ph.D., President and Chief Executive Officer at Arvinas. “Resistance to immunotherapy remains a significant challenge; to date, combinations targeting other immune pathways have not provided a reliable way to prevent or reverse it. The encouraging preclinical data for ARV-6723 – including activity in models resistant to immune checkpoint inhibitors – support clinical investigation of its potential to address this unmet need for patients.”

The ARV-6723-101 Phase 1/2 clinical trial (NCT07749586) is a global, multicenter trial designed to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of orally administered ARV-6723 as a monotherapy or in combination with pembrolizumab in adults with advanced solid tumors. The first-in-human trial will initially evaluate the safety of ARV-6723 as a monotherapy treatment and subsequently in combination with an anti-PD-1 therapy, while also evaluating whether deep and sustained HPK1 degradation translates into meaningful antitumor effects in patients. The initial monotherapy cohort of this trial is enrolling patients who have received a prior immune checkpoint inhibitor and have no suitable standard treatment options.

About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas, with its partner Pfizer, developed the first U.S. Food and Drug Administration (FDA)-approved PROTAC, a type of heterobifunctional protein degrader, which has been outlicensed to Rigel Pharmaceuticals, Inc. for exclusive global development, manufacturing, and commercialization.

Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle for spinal-bulbar muscular atrophy, also known as Kennedy’s disease; and ARV-6723, targeting HPK1 for advanced solid tumors. Arvinas has also advanced ARV-806, targeting KRAS G12D for solid tumors, in the clinic, and previously announced plans to seek an out-licensing agreement for any additional clinical trials of ARV-806, including dose expansion or combination clinical trials. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.

About ARV-6723
ARV-6723 is an investigational, oral PROTAC designed to degrade hematopoietic progenitor kinase 1 (HPK1) and is Arvinas’ first clinical candidate in the immuno-oncology space. HPK1 is a negative regulator of immune activation expressed across multiple immune cell types, including T cells, B cells, natural killer cells, and dendritic cells. Preclinically, ARV-6723 demonstrated potent, selective HPK1 degradation and greater tumor growth inhibition across low- and high-immunogenic tumor models, including anti-PD-1 resistant tumor models. By removing HPK1, ARV-6723 may address both its kinase-dependent and kinase-independent functions and enhance antitumor immune activity. ARV-6723 is currently being evaluated in a first-in-human Phase 1/2 clinical trial in patients with advanced solid tumors.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding: the potential of ARV-6723, including its degradation of hematopoietic progenitor kinase 1 (“HPK1”), and its potential treatment of advanced solid tumors; whether by removing HPK1, ARV-6723 may address both its kinase-dependent and kinase-independent functions and enhance antitumor immune activity; preclinical ARV-6723 data supporting the clinical evaluation of ARV-6723 both as monotherapy and in combination with an anti-PD-1 therapy; whether ARV-6723’s design to degrade and remove the HPK1 protein and its signaling scaffolding will address functions of HPK1 that may not be fully addressed by traditional inhibitors; Arvinas’ plans with respect to ARV-6723 and its development; and Arvinas’ plans to outlicense ARV-806. All statements, other than statements of historical fact, contained in this press release, including statements regarding Arvinas’ strategy, development plans, future operations, prospects, plans, and objectives of management and the statements identified in the prior paragraph, are forward-looking statements. The words “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “target,” “goal,” “aim,” “whether,” “will,” “would,” “could,” “reliance,” “should,” “look forward,” “seek,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Arvinas may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: whether Arvinas will be able to successfully conduct and complete development for its product candidates, including ARV-6723, on its current timelines or at all; risks related to clinical trial results and the interpretation thereof, including with respect to ARV-6723; that the results of preclinical studies may not be predictive of the results of clinical trials; Arvinas’ ability to protect its intellectual property portfolio; Arvinas’ reliance on third parties; whether Arvinas will be able to raise capital when needed; whether Arvinas’ cash and cash equivalents will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the “Risk Factors” section of Arvinas’ Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent other reports filed with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas’ current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas’ views as of any date subsequent to the date of this release.

Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com

Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com

LONDON and RIYADH, Saudi Arabia, Sept. 28, 2026 (GLOBE NEWSWIRE) — Virtu Financial, Inc. (NYSE: VIRT), a leading provider of global, multi-asset financial services that delivers liquidity and innovative, transparent products across the complete investment cycle to global markets, today announced the launch of POSIT^® block-trading indications network for equity securities listed on the Saudi Exchange.

The addition of 245 of the most liquid Saudi Exchange-listed securities to the POSIT block-trading indications network gives Saudi Exchange members and their institutional clients access to Virtu’s established global network for sourcing block liquidity via Al Rajhi Capital, Virtu’s regional partner. Saudi Exchange members and their clients will be offered aggregation capabilities when accessing the POSIT block-trading indications network to further enhance workflow for investors.

Using the Negotiated Deals facility of the Saudi Exchange gives exchange members greater flexibility to execute large transactions on-platform. Virtu is leveraging the Saudi Exchange’s fully electronic Negotiated Deals facility to enable the completion of the block trades sourced through the POSIT system. All trades will settle on a T+2 basis through The Securities Depository Center Company (Edaa) — the standard settlement cycle used for Saudi Exchange trades. For firms that are not direct Saudi Exchange members, connectivity, brokerage, and post-trade services are provided by Al Rajhi Capital.

Mohammed Al-Rumaih, Chief Executive Officer of the Saudi Exchange said, “The integration of Saudi-listed securities into global institutional trading workflows reflects the continued evolution of the Saudi Capital Market and its increasing connectivity with international investors. At Saudi Exchange, we have consistently invested in market infrastructure, accessibility and efficiency, and we welcome developments that complement these efforts by providing institutional investors with additional ways to source liquidity and participate in our market.”

“Deploying POSIT technologies to Saudi-listed securities further enhances the appeal and accessibility of Saudi equity capital markets to global institutional investors,” said Rob Boardman, CEO of Virtu Execution Services, EMEA. “This initiative would have been impossible without the innovation and assistance provided by the Saudi Exchange and our local partners Al Rajhi Capital and Arqaam Capital.”

“Availability of block liquidity can lower the implementation cost of equity transactions, which benefits our clients, so we are pleased to use the new POSIT facility” said Graham Sorrell, Head of EMEA & APAC Equity and Currency Trading at State Street Investment Management, which conducted the first transaction on the platform. “This exciting development for the region speaks to the rapid evolution of the Kingdom’s market infrastructure and clearly demonstrates growing appeal of the Saudi market as a destination for capital and increased innovation in the market.”

“At Al Rajhi Capital we value partnerships very highly,” said Hossam Basrawi, Chief Executive Officer at Al Rajhi Capital. “We are delighted to participate in the launch of POSIT for Saudi equities in partnership with Virtu. This effort reflects our commitment to developing the electronic trading ecosystem of Saudi Arabia and providing institutional investors with world-class trading solutions.”

About Virtu Financial
Virtu Financial is comprised of companies and financial services firms that leverage cutting-edge technology to deliver liquidity to the global markets and innovative, transparent trading solutions to our clients. Virtu operates one of the world’s longest-running and most widely used electronic block-trading networks, serving institutional asset managers globally. For more information about Virtu’s POSIT block indications network and other workflow tools, please visit our client solutions page at virtu.com.

For more information, please contact:
Matt Sandberg
Investor Relations
investor_relations@virtu.com

Petri Darby
Media
media@virtu.com

LONDON and RIYADH, Saudi Arabia, Sept. 28, 2026 (GLOBE NEWSWIRE) — Virtu Financial, Inc. (NYSE: VIRT), a leading provider of global, multi-asset financial services that delivers liquidity and innovative, transparent products across the complete investment cycle to global markets, today announced the launch of POSIT^® block-trading indications network for equity securities listed on the Saudi Exchange.

The addition of 245 of the most liquid Saudi Exchange-listed securities to the POSIT block-trading indications network gives Saudi Exchange members and their institutional clients access to Virtu’s established global network for sourcing block liquidity via Al Rajhi Capital, Virtu’s regional partner. Saudi Exchange members and their clients will be offered aggregation capabilities when accessing the POSIT block-trading indications network to further enhance workflow for investors.

Using the Negotiated Deals facility of the Saudi Exchange gives exchange members greater flexibility to execute large transactions on-platform. Virtu is leveraging the Saudi Exchange’s fully electronic Negotiated Deals facility to enable the completion of the block trades sourced through the POSIT system. All trades will settle on a T+2 basis through The Securities Depository Center Company (Edaa) — the standard settlement cycle used for Saudi Exchange trades. For firms that are not direct Saudi Exchange members, connectivity, brokerage, and post-trade services are provided by Al Rajhi Capital.

Mohammed Al-Rumaih, Chief Executive Officer of the Saudi Exchange said, “The integration of Saudi-listed securities into global institutional trading workflows reflects the continued evolution of the Saudi Capital Market and its increasing connectivity with international investors. At Saudi Exchange, we have consistently invested in market infrastructure, accessibility and efficiency, and we welcome developments that complement these efforts by providing institutional investors with additional ways to source liquidity and participate in our market.”

“Deploying POSIT technologies to Saudi-listed securities further enhances the appeal and accessibility of Saudi equity capital markets to global institutional investors,” said Rob Boardman, CEO of Virtu Execution Services, EMEA. “This initiative would have been impossible without the innovation and assistance provided by the Saudi Exchange and our local partners Al Rajhi Capital and Arqaam Capital.”

“Availability of block liquidity can lower the implementation cost of equity transactions, which benefits our clients, so we are pleased to use the new POSIT facility” said Graham Sorrell, Head of EMEA & APAC Equity and Currency Trading at State Street Investment Management, which conducted the first transaction on the platform. “This exciting development for the region speaks to the rapid evolution of the Kingdom’s market infrastructure and clearly demonstrates growing appeal of the Saudi market as a destination for capital and increased innovation in the market.”

“At Al Rajhi Capital we value partnerships very highly,” said Hossam Basrawi, Chief Executive Officer at Al Rajhi Capital. “We are delighted to participate in the launch of POSIT for Saudi equities in partnership with Virtu. This effort reflects our commitment to developing the electronic trading ecosystem of Saudi Arabia and providing institutional investors with world-class trading solutions.”

About Virtu Financial
Virtu Financial is comprised of companies and financial services firms that leverage cutting-edge technology to deliver liquidity to the global markets and innovative, transparent trading solutions to our clients. Virtu operates one of the world’s longest-running and most widely used electronic block-trading networks, serving institutional asset managers globally. For more information about Virtu’s POSIT block indications network and other workflow tools, please visit our client solutions page at virtu.com.

For more information, please contact:
Matt Sandberg
Investor Relations
investor_relations@virtu.com

Petri Darby
Media
media@virtu.com

–        Pooled analysis of five clinical trials found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional anthracycline limits

–      Independent Cleveland Clinic cardio-oncology evaluation supports continued clinical development of Annamycin as a potentially safer anthracycline

HOUSTON, Sept. 28, 2026 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced the publication of a peer-reviewed analysis of the cardiac safety of Annamycin (also known as L-Annamycin or naxtarubicin) in Frontiers in Cardiovascular Medicine. The publication, titled “Cardiac safety of L-Annamycin: a pooled analysis of five clinical trials,” reports cardiac safety findings from 90 patients treated across five clinical trials in acute myeloid leukemia (AML) and metastatic soft tissue sarcoma (STS).

The analysis was independently evaluated by a cardio-oncology laboratory at Cleveland Clinic and found no clinical or subclinical evidence of treatment-related cardiotoxicity, including at cumulative Annamycin exposures exceeding traditional lifetime limits for conventional anthracyclines.

“Publication of this comprehensive pooled analysis in a peer-reviewed cardiovascular medicine journal provides additional validation of the cardiac safety profile we have observed with Annamycin across our clinical development program,” said Walter Klemp, Chairman and Chief Executive Officer of Moleculin. “For decades, the clinical utility of anthracyclines has been limited by cumulative cardiotoxicity and associated lifetime dose limits. The absence of detectable cardiac toxicity in patients receiving cumulative doses of Annamycin beyond those traditional thresholds supports our continued development of Annamycin and its potential to address an important limitation of the anthracycline class.”

Pooled Analysis Evaluates Cardiac Safety Across Five Clinical Trials

The publication evaluated cardiac safety data from five sponsor- and investigator-initiated clinical trials, including three trials in AML and two trials in metastatic STS. Across the five studies, 90 patients received Annamycin, with paired echocardiographic data available for 78 patients.

Key findings from the pooled analysis include:

• No significant change in cardiac function: Mean LVEF was 60.6% at baseline compared with 60.0% following treatment, with no statistically significant difference (p=0.84).
• No relationship between cumulative dose and change in LVEF: The analysis found no association between cumulative Annamycin exposure and changes in LVEF.
• No relationship between age and change in LVEF: Patient age was not associated with changes in LVEF.
• No treatment-related cardiotoxicity identified: Serial ECGs, cardiac biomarkers including troponin I/T, and global longitudinal strain assessments showed no evidence of treatment-related cardiotoxicity.
• High cumulative exposure: Patients received a median cumulative Annamycin dose of 660 mg/m², with findings observed despite cumulative exposures exceeding conventional anthracycline lifetime limits.

The authors concluded that Annamycin was not associated with clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional anthracycline thresholds and that the findings support continued clinical evaluation of Annamycin as a potentially safer anthracycline platform.

Anthracyclines are among the most widely used and effective classes of cancer medicines, but their use can be limited by cumulative, dose-dependent cardiotoxicity. These cardiac risks can restrict treatment intensity, limit retreatment options and prevent some patients from receiving additional anthracycline therapy.

Annamycin is a fundamentally re-engineered anthracycline designed to maintain the antitumor activity of the anthracycline class while addressing the cardiotoxicity associated with conventional agents. Its liposomal formulation was developed to optimize tissue distribution and reduce cardiac exposure.

The newly published article builds upon previously presented clinical data demonstrating a lack of detectable cardiotoxicity with Annamycin despite cumulative exposure levels substantially exceeding conventional anthracycline limits. Moleculin previously reported that the pooled analysis included 90 patients across five completed clinical trials, with independent cardiac review conducted through the Cleveland Clinic Division of Cardiovascular Medicine.

Annamycin is currently being evaluated in Moleculin’s MIRACLE clinical development program for patients with relapsed or refractory AML.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a Phase 2/3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), is a highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design, multi-center, randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as “Ara-C”) for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential efficacy and safety of Annamycin and AnnAraC in R/R AML, the potential immune-mediated mechanism of action of Annamycin, the relevance of preclinical findings in pancreatic cancer to the treatment of human disease, and the potential for Annamycin to be combined with other agents. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com

–        Pooled analysis of five clinical trials found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional anthracycline limits

–      Independent Cleveland Clinic cardio-oncology evaluation supports continued clinical development of Annamycin as a potentially safer anthracycline

HOUSTON, Sept. 28, 2026 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced the publication of a peer-reviewed analysis of the cardiac safety of Annamycin (also known as L-Annamycin or naxtarubicin) in Frontiers in Cardiovascular Medicine. The publication, titled “Cardiac safety of L-Annamycin: a pooled analysis of five clinical trials,” reports cardiac safety findings from 90 patients treated across five clinical trials in acute myeloid leukemia (AML) and metastatic soft tissue sarcoma (STS).

The analysis was independently evaluated by a cardio-oncology laboratory at Cleveland Clinic and found no clinical or subclinical evidence of treatment-related cardiotoxicity, including at cumulative Annamycin exposures exceeding traditional lifetime limits for conventional anthracyclines.

“Publication of this comprehensive pooled analysis in a peer-reviewed cardiovascular medicine journal provides additional validation of the cardiac safety profile we have observed with Annamycin across our clinical development program,” said Walter Klemp, Chairman and Chief Executive Officer of Moleculin. “For decades, the clinical utility of anthracyclines has been limited by cumulative cardiotoxicity and associated lifetime dose limits. The absence of detectable cardiac toxicity in patients receiving cumulative doses of Annamycin beyond those traditional thresholds supports our continued development of Annamycin and its potential to address an important limitation of the anthracycline class.”

Pooled Analysis Evaluates Cardiac Safety Across Five Clinical Trials

The publication evaluated cardiac safety data from five sponsor- and investigator-initiated clinical trials, including three trials in AML and two trials in metastatic STS. Across the five studies, 90 patients received Annamycin, with paired echocardiographic data available for 78 patients.

Key findings from the pooled analysis include:

• No significant change in cardiac function: Mean LVEF was 60.6% at baseline compared with 60.0% following treatment, with no statistically significant difference (p=0.84).
• No relationship between cumulative dose and change in LVEF: The analysis found no association between cumulative Annamycin exposure and changes in LVEF.
• No relationship between age and change in LVEF: Patient age was not associated with changes in LVEF.
• No treatment-related cardiotoxicity identified: Serial ECGs, cardiac biomarkers including troponin I/T, and global longitudinal strain assessments showed no evidence of treatment-related cardiotoxicity.
• High cumulative exposure: Patients received a median cumulative Annamycin dose of 660 mg/m², with findings observed despite cumulative exposures exceeding conventional anthracycline lifetime limits.

The authors concluded that Annamycin was not associated with clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional anthracycline thresholds and that the findings support continued clinical evaluation of Annamycin as a potentially safer anthracycline platform.

Anthracyclines are among the most widely used and effective classes of cancer medicines, but their use can be limited by cumulative, dose-dependent cardiotoxicity. These cardiac risks can restrict treatment intensity, limit retreatment options and prevent some patients from receiving additional anthracycline therapy.

Annamycin is a fundamentally re-engineered anthracycline designed to maintain the antitumor activity of the anthracycline class while addressing the cardiotoxicity associated with conventional agents. Its liposomal formulation was developed to optimize tissue distribution and reduce cardiac exposure.

The newly published article builds upon previously presented clinical data demonstrating a lack of detectable cardiotoxicity with Annamycin despite cumulative exposure levels substantially exceeding conventional anthracycline limits. Moleculin previously reported that the pooled analysis included 90 patients across five completed clinical trials, with independent cardiac review conducted through the Cleveland Clinic Division of Cardiovascular Medicine.

Annamycin is currently being evaluated in Moleculin’s MIRACLE clinical development program for patients with relapsed or refractory AML.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a Phase 2/3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), is a highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design, multi-center, randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as “Ara-C”) for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential efficacy and safety of Annamycin and AnnAraC in R/R AML, the potential immune-mediated mechanism of action of Annamycin, the relevance of preclinical findings in pancreatic cancer to the treatment of human disease, and the potential for Annamycin to be combined with other agents. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com

NEWMARKET, Ontario, Sept. 28, 2026 (GLOBE NEWSWIRE) — AirBoss of America Corp. (TSX: BOS) (OTCQX:ABSSF) (the “Company” or “AirBoss”) today announced that AirBoss Defense Group (“ADG”), AirBoss Manufactured Products’ defense business, has been awarded a five-year framework contract for its Bandolier lightweight, multipurpose energetic system by a NATO partner nation, with an option to renew for an additional five years. Accompanying the framework contract is an initial delivery order worth up to US$12.5 million. Subject to satisfaction of customary conditions, deliveries are expected to occur during the fourth quarter of 2026 and first half of 2027.

ADG has also recently received orders for AirBoss Molded Gloves (“AMG”) and Molded AirBoss Lightweight Overboots (“MALO”) from several NATO partner nations, worth up to US$4.4 million, with deliveries expected to occur during 2026 and 2027.

The Bandolier is a lightweight and modular energetic system that can be employed across mobility, counter mobility, and survivability mission profiles. The Bandolier is designed to bridge the identified capability gap between large, complex, single-role explosive charges and standard bulk demolitions, and its lightweight, modular design allows for flexible use across a variety of mission requirements. The system reduces dependence on cumbersome single-role explosives and time-consuming user-constructed charges, maximizing explosive efficiency and operational versatility.

“The Bandolier continues to demonstrate strong demand from NATO and allied customers as modern battlefield requirements evolve,” said Chris Bitsakakis, President and Co-CEO of AirBoss. “Its highly versatile, modular design enables operators to address a wide range of battlefield challenges while supporting deployment through both traditional and emerging autonomous delivery systems. We believe this multi-year framework contract further validates the Bandolier’s differentiated capabilities, while the other recent awards more broadly reflect continued demand for ADG’s portfolio of survivability solutions among NATO partners.”

This new Bandolier award builds upon other recent contracts received by ADG for this product, reinforcing AirBoss’ position as a leading provider of advanced battlefield survivability solutions.

About AirBoss

AirBoss of America is a diversified developer, manufacturer and provider of survivability solutions, advanced custom rubber and polymer compounds and finished products that are designed to outperform in the most challenging environments. Founded in 1989, the company operates through two divisions. AirBoss Rubber Solutions is a North American custom rubber compounder with 500 million turn pounds of annual capacity. AirBoss Manufactured Products is a supplier of anti-vibration and rubber-molded solutions to the North American automotive market and other sectors, and also a global supplier of personal and respiratory protective equipment and technology for the defense, healthcare, medical and first responder communities, through its AirBoss Defense operations. The Company’s shares trade on the TSX under the symbol BOS and on the OTCQX under the symbol ABSSF. Visit www.airboss.com for more information.

AIRBOSS FORWARD LOOKING INFORMATION DISCLAIMER

Certain statements contained or incorporated by reference herein, including those that express management’s expectations or estimates of future developments or AirBoss’ future performance, constitute “forward-looking information” or “forward-looking statements” within the meaning of applicable securities laws, and can generally be identified by words such as “will”, “may”, “could” “expects”, “believes”, “anticipates”, “forecasts”, “plans”, “intends”, “should” or similar expressions. These statements are not historical facts but instead represent management’s expectations, estimates and projections regarding future events and performance.

Statements containing forward-looking information are necessarily based upon a number of opinions, estimates and assumptions that, while considered reasonable by management at the time the statements are made, are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. AirBoss cautions that such forward-looking information involves known and unknown contingencies, uncertainties and other risks that may cause AirBoss’ actual financial results, performance or achievements to be materially different from its estimated future results, performance or achievements expressed or implied by the forward-looking information. Numerous factors could cause actual results to differ materially from those in the forward-looking information, including without limitation: impact of general economic conditions, notably including its impact on demand for rubber solutions and products; dependence on key customers; global defense budgets, notably in the Company’s target markets, and success of the Company in obtaining new or extended defense contracts; contract-related risks; cyclical trends in the tire and automotive, construction, mining and retail industries; sufficient availability of raw materials at economical costs; weather conditions affecting raw materials, production and sales; global political uncertainty and policy change; AirBoss’ ability to maintain existing customers or develop new customers in light of increased competition; AirBoss’ ability to successfully integrate acquisitions of other businesses and/or companies or to realize on the anticipated benefits thereof; AirBoss’ ability to successfully develop and execute effective business strategies including, without limitation, the recently announced strategic transition; changes in accounting policies and methods, including uncertainties associated with critical accounting assumptions and estimates; changes in the value of the Canadian dollar relative to the US dollar; changes in tax laws; changes in trade policies or the imposition of new tariffs, duties or other similar restrictions which could influence the cost and flow of goods and services across borders; current and future litigation and regulatory actions; ability to obtain financing on acceptable terms and ability to satisfy the covenants set forth in such financing arrangements; environmental damage and non-compliance with environmental laws and regulations; impact of global health situations; IT/cybersecurity risks; potential product liability and warranty claims and equipment malfunction. There is increased uncertainty associated with future operating assumptions and expectations as compared to prior periods. This list is not exhaustive of the factors that may affect any of AirBoss’ forward-looking information.

All of the forward-looking information in this press release is expressly qualified by these cautionary statements. Investors are cautioned not to put undue reliance on forward-looking information. All subsequent written and oral forward-looking information attributable to AirBoss or persons acting on its behalf are expressly qualified in their entirety by this notice. Forward-looking information contained herein is made as of the date of this press release and, whether as a result of new information, future events or otherwise, AirBoss disclaims any intent or obligation to update publicly the forward-looking information except as required by applicable laws. Risks and uncertainties about AirBoss’ business are more fully discussed under the heading “Risk Factors” in our most recent Annual Information Form and are otherwise disclosed in our filings with securities regulatory authorities which are available on SEDAR+ at www.sedarplus.com.

CONTACT: Investor Contact: investor.relations@airboss.com

Media Contact: media@airboss.com

NEWMARKET, Ontario, Sept. 28, 2026 (GLOBE NEWSWIRE) — AirBoss of America Corp. (TSX: BOS) (OTCQX:ABSSF) (the “Company” or “AirBoss”) today announced that AirBoss Defense Group (“ADG”), AirBoss Manufactured Products’ defense business, has been awarded a five-year framework contract for its Bandolier lightweight, multipurpose energetic system by a NATO partner nation, with an option to renew for an additional five years. Accompanying the framework contract is an initial delivery order worth up to US$12.5 million. Subject to satisfaction of customary conditions, deliveries are expected to occur during the fourth quarter of 2026 and first half of 2027.

ADG has also recently received orders for AirBoss Molded Gloves (“AMG”) and Molded AirBoss Lightweight Overboots (“MALO”) from several NATO partner nations, worth up to US$4.4 million, with deliveries expected to occur during 2026 and 2027.

The Bandolier is a lightweight and modular energetic system that can be employed across mobility, counter mobility, and survivability mission profiles. The Bandolier is designed to bridge the identified capability gap between large, complex, single-role explosive charges and standard bulk demolitions, and its lightweight, modular design allows for flexible use across a variety of mission requirements. The system reduces dependence on cumbersome single-role explosives and time-consuming user-constructed charges, maximizing explosive efficiency and operational versatility.

“The Bandolier continues to demonstrate strong demand from NATO and allied customers as modern battlefield requirements evolve,” said Chris Bitsakakis, President and Co-CEO of AirBoss. “Its highly versatile, modular design enables operators to address a wide range of battlefield challenges while supporting deployment through both traditional and emerging autonomous delivery systems. We believe this multi-year framework contract further validates the Bandolier’s differentiated capabilities, while the other recent awards more broadly reflect continued demand for ADG’s portfolio of survivability solutions among NATO partners.”

This new Bandolier award builds upon other recent contracts received by ADG for this product, reinforcing AirBoss’ position as a leading provider of advanced battlefield survivability solutions.

About AirBoss

AirBoss of America is a diversified developer, manufacturer and provider of survivability solutions, advanced custom rubber and polymer compounds and finished products that are designed to outperform in the most challenging environments. Founded in 1989, the company operates through two divisions. AirBoss Rubber Solutions is a North American custom rubber compounder with 500 million turn pounds of annual capacity. AirBoss Manufactured Products is a supplier of anti-vibration and rubber-molded solutions to the North American automotive market and other sectors, and also a global supplier of personal and respiratory protective equipment and technology for the defense, healthcare, medical and first responder communities, through its AirBoss Defense operations. The Company’s shares trade on the TSX under the symbol BOS and on the OTCQX under the symbol ABSSF. Visit www.airboss.com for more information.

AIRBOSS FORWARD LOOKING INFORMATION DISCLAIMER

Certain statements contained or incorporated by reference herein, including those that express management’s expectations or estimates of future developments or AirBoss’ future performance, constitute “forward-looking information” or “forward-looking statements” within the meaning of applicable securities laws, and can generally be identified by words such as “will”, “may”, “could” “expects”, “believes”, “anticipates”, “forecasts”, “plans”, “intends”, “should” or similar expressions. These statements are not historical facts but instead represent management’s expectations, estimates and projections regarding future events and performance.

Statements containing forward-looking information are necessarily based upon a number of opinions, estimates and assumptions that, while considered reasonable by management at the time the statements are made, are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. AirBoss cautions that such forward-looking information involves known and unknown contingencies, uncertainties and other risks that may cause AirBoss’ actual financial results, performance or achievements to be materially different from its estimated future results, performance or achievements expressed or implied by the forward-looking information. Numerous factors could cause actual results to differ materially from those in the forward-looking information, including without limitation: impact of general economic conditions, notably including its impact on demand for rubber solutions and products; dependence on key customers; global defense budgets, notably in the Company’s target markets, and success of the Company in obtaining new or extended defense contracts; contract-related risks; cyclical trends in the tire and automotive, construction, mining and retail industries; sufficient availability of raw materials at economical costs; weather conditions affecting raw materials, production and sales; global political uncertainty and policy change; AirBoss’ ability to maintain existing customers or develop new customers in light of increased competition; AirBoss’ ability to successfully integrate acquisitions of other businesses and/or companies or to realize on the anticipated benefits thereof; AirBoss’ ability to successfully develop and execute effective business strategies including, without limitation, the recently announced strategic transition; changes in accounting policies and methods, including uncertainties associated with critical accounting assumptions and estimates; changes in the value of the Canadian dollar relative to the US dollar; changes in tax laws; changes in trade policies or the imposition of new tariffs, duties or other similar restrictions which could influence the cost and flow of goods and services across borders; current and future litigation and regulatory actions; ability to obtain financing on acceptable terms and ability to satisfy the covenants set forth in such financing arrangements; environmental damage and non-compliance with environmental laws and regulations; impact of global health situations; IT/cybersecurity risks; potential product liability and warranty claims and equipment malfunction. There is increased uncertainty associated with future operating assumptions and expectations as compared to prior periods. This list is not exhaustive of the factors that may affect any of AirBoss’ forward-looking information.

All of the forward-looking information in this press release is expressly qualified by these cautionary statements. Investors are cautioned not to put undue reliance on forward-looking information. All subsequent written and oral forward-looking information attributable to AirBoss or persons acting on its behalf are expressly qualified in their entirety by this notice. Forward-looking information contained herein is made as of the date of this press release and, whether as a result of new information, future events or otherwise, AirBoss disclaims any intent or obligation to update publicly the forward-looking information except as required by applicable laws. Risks and uncertainties about AirBoss’ business are more fully discussed under the heading “Risk Factors” in our most recent Annual Information Form and are otherwise disclosed in our filings with securities regulatory authorities which are available on SEDAR+ at www.sedarplus.com.

CONTACT: Investor Contact: investor.relations@airboss.com

Media Contact: media@airboss.com

Modular Architecture Is Designed to Support ISR, Logistics, Counter-UAS, RF Sensing, Remote Weapon Stations and Specialized Mission Payloads

WEST HOLLYWOOD, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) — VisionWave Holdings, Inc. (Nasdaq: VWAV) (“VisionWave” or the “Company”) today highlighted its STRATUM autonomous ground systems architecture, a family of modular unmanned ground platforms, each of which is in development, designed to support multiple defense, security and logistics missions from a common technology foundation. No platform in the STRATUM ground family has completed qualification testing, entered serial production, been sold to a customer or generated revenue.

VisionWave’s ground development programs include the VARAN, RANGER, SCOUT and RECON platforms, each of which is in development and each designed around the concept that the vehicle remains consistent while the mission module can change based on operational requirements. 

The Company believes this payload-agnostic approach can allow military and security operators to deploy a common autonomous platform architecture across a range of missions rather than maintaining separate vehicles for every application.

VARAN: A Modular Ground Platform

The VARAN platform is being designed to target specifications that include a payload capacity of approximately 500 kilograms, towing capacity exceeding 1,000 kilograms, maximum speed of approximately 70 km/h (45 mph) and mission time of approximately four hours, extendable to 28 hours depending upon configuration and operating conditions. These figures are design objectives. The platform has not completed testing to validate them, and actual performance may differ materially from the design objectives described. 

Mission configurations contemplated by VisionWave, none of which has completed integration and testing on the platform, include:

• Drone launch and recovery canisters;
• Remote weapon stations;
• Radar and RF sensing;
• ISR and optical mast systems;
• Logistics and resupply; and
• Medical, EOD, electronic warfare and route-clearance modules. 

“The important concept behind STRATUM is modularity,” said Douglas Davis, Chief Executive Officer and Executive Chairman of VisionWave. “Instead of designing a new vehicle around every mission, our architecture is intended to allow the mission package to change while maintaining a common platform, logistics structure and command environment.”

Connecting Ground and Air

VisionWave is also designing its ground platforms to operate alongside tactical aerial assets.

Under the Company’s ecosystem approach, aerial systems are intended to be capable of being launched from or operating alongside ground elements, sharing a common mission picture and ultimately being tasked through the STRATUM command environment. That capability has not been demonstrated.

This architecture is intended to create a unified operating model spanning unmanned ground vehicles, aerial systems, sensors and mission intelligence. 

“Our objective is not simply autonomous mobility,” Davis added. “It is autonomous mission execution—connecting mobility, sensing, aerial assets and intelligence into one operational architecture.”

The platforms, mission modules and capabilities described herein are under development, have not completed testing or qualification, are not commercially available and have not generated revenue. They remain subject to testing, evaluation, export authorization and applicable regulatory and procurement requirements, and there can be no assurance that they will be completed, will achieve their intended performance or will be adopted by any customer.

ABOUT VISIONWAVE

VisionWave Holdings, Inc. (Nasdaq: VWAV) is a defense and advanced sensing technology company developing AI-driven, RF-based sensing, autonomy, and computational acceleration technologies for defense, homeland security, and commercial infrastructure applications. VisionWave’s mission is to connect defense innovation with civilian progress through shared core technologies intended for use across air, land and fixed-site environments. The Company’s website is https://www.vwav.inc. Information contained on, or accessible through, the Company’s website is not incorporated by reference into, and does not form a part of, this press release or any filing of the Company with the Securities and Exchange Commission. Certain of the platforms, payloads, sensing technologies and software described in this press release are in development, have not completed testing or qualification, are not commercially available and have not generated material revenue.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are generally identified by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “project,” “forecast,” “predict,” “target,” “objective,” “strategy,” “designed to,” “intended to,” “concept,” “under development” and similar expressions, or by statements that events or trends “may,” “will,” or “could” occur. Forward-looking statements in this press release include, without limitation, statements regarding the intended design, configuration, performance, payload capacity, towing capacity, speed, endurance and mission modules of the VARAN, RANGER, SCOUT and RECON platforms; the intended modularity and payload-agnostic architecture of the STRATUM ground systems; and the intended interoperability of ground platforms with aerial systems and with the STRATUM command environment.

Forward-looking statements are not guarantees of future performance, are based on management’s current expectations and assumptions as of the date of this press release, and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied, including, but not limited to: the fact that substantially all of the platforms, payloads, sensing technologies and software described in this press release are in development, have not completed testing, qualification or independent third-party validation, are not commercially available, have not generated material revenue, and may never be completed, certified, produced at scale or adopted by any customer; the Company’s need to raise substantial additional capital to fund development and its ability to do so on acceptable terms or at all; the substantial dilution to existing stockholders resulting from sales of common stock under the Company’s at-the-market offering programs, conversions of the Company’s outstanding convertible debentures, exercises of outstanding warrants and shares issuable as consideration in acquisitions and strategic transactions; the Company’s history of operating losses, accumulated deficit and working capital deficiency, and the substantial doubt regarding the Company’s ability to continue as a going concern described in its most recent periodic report; the Company’s ability to satisfy the continued listing standards of The Nasdaq Stock Market, including the minimum bid price requirement, and the anticipated effects of the reverse stock split approved by the Company’s stockholders; the Company’s dependence on government procurement processes, competitive solicitations, budget appropriations and program funding, none of which has resulted in an award, contract or order to the Company; the risks of pursuing sales to foreign governments and foreign defense ministries, including procurement delays, offset requirements, political and geopolitical developments and the absence of any binding commitment; U.S. and non-U.S. export control, licensing, technology transfer, defense trade registration and economic sanctions requirements applicable to the technologies described in this press release, including the International Traffic in Arms Regulations and the Export Administration Regulations, and the risk that required authorizations are delayed, conditioned or denied; the Company’s ability to obtain, protect and enforce intellectual property rights and the risk that pending patent applications do not issue; risks relating to acquisitions, integration and reliance on third parties, partners, suppliers and subcontractors; and the other risks and uncertainties described under “Risk Factors” in the Company’s Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q and its Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission.

All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release and in the Company’s SEC filings. VisionWave undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. Investors are cautioned not to place undue reliance on these forward-looking statements.

Contact for Investors: investors@vwav.inc